International Journal of Rheumatology / 2017 / Article / Tab 1 / Clinical Study
Effect of Curcuma xanthorrhiza Supplementation on Systemic Lupus Erythematosus Patients with Hypovitamin D Which Were Given Vitamin D3 towards Disease Activity (SLEDAI), IL-6, and TGF-β 1 Serum Table 1 Baseline characteristics of subjects.
Characteristics Vitamin D3 + placebo ( = 20) Vitamin D3 + Curcuma xanthorrhiza ( = 19) valueAge (y.o.) (mean ± SD) 30.3 ± 10.0 27.9 ± 7.9 0.415 Illness duration (years) (median; IQR) 2.25 (IQR: 1.0–4.0) 2.0 (IQR: 1.0–4.0) 0.937 Body mass index (kg/m2 ) (median; IQR) 20.8 (IQR: 16.4–27.3) 20.8 (IQR: 17.1–28.3) 0.915 SLEDAI (mean ± SD) 15.1 ± 7.6 15.2 ± 7.4 0.879 Early manifestation (%) Mucocutan 17 (43.6%) 13 (33.3%) 0.219 Arthritis 9 (23.1%) 7 (17.9%) 0.605 Nephritis (proteinuria, hematuria, pyuria, cylindruria) 4 (10.3%) 8 (20.5%) 0.135 Hematology (AIHA, leucopenia, thrombocytopenia) 2 (5.1%) 3 (7.7%) 0.589 Vasculitis 1 (2.6%) 1 (2.6%) 0.970 Serositis 1 (2.6%) 1 (2.6%) 0.970 Cerebral 3 (7.7%) 4 (10.3%) 0.622 Medications (%) (a) Non-Immunosuppressants (i) Methylprednisolone (<8 mg/day) 19 (48.7%) 19 (48.7%) 0.323 (ii) Calcium Carbonate 19 (48.7%) 15 (38.5%) 0.134 (b) Immunosuppressants (i) Chloroquine 10 (25.6%) 7 (17.9%) 0.408 (ii) Cyclosporine 2 (5.1%) 0 (0%) 0.157 (iii) Cyclophosphamide 1 (2.6%) 5 (12.8%) 0.065 (iv) Azathioprine 10 (25.6%) 14 (35.9%) 0.129 (v) Mofetil mycophenolate 0 (0%) 0 (0%) —
IQR: interquartile.